GlobeNewswire by notified

C. Hasse & Sohn Announces a 5-Years License agreement to Photocat NOxOFF Technology to produce in Uelzen, Germany


May 13th 2024

C. Hasse & Sohn Announces a 5-Years License agreement to Photocat NOxOFF Technology to produce in Uelzen, Germany

Roskilde, Denmark. May 13, 2024 – Photocat, a leading developer and provider of photocatalytic solutions for air purification, is pleased to announce a strategic partnership with C. Hasse & Sohn, a prominent German bitumen roofing company. This License agreement follows agreements made with IKO, Danosa and Katepal to use IPR developed and owned by Photocat. The IPR portfolio supported with Knowhow transfers provide the partners/Licensees with data and values to support the documentation of the environmental impact and improved air quality properties. We build a better air quality one roof at a time.

Key Partnership Highlights:

  • Five-Year Commitment: Under this agreement, Photocat and C. Hasse & Sohn have committed to a five-year partnership dedicated to advancing NOx reduction technology and promoting sustainable solutions in the German market.
  • Competitive Photocatalytic Technology: Photocat will provide access to its proprietary and patented photocatalytic technology, which will be integrated into selected parts of C. Hasse & Sohn's product portfolio – under their brand name Kubidritt ReduX. Leveraging Photocat's extensive patent base, developed at the company's headquarters in Denmark, this collaboration represents a significant step forward in bringing cutting-edge air purification solutions to the roofing industry while ensuring the protection of intellectual property rights.
  • Sustainable Impact: Through this partnership, Photocat and C. Hasse & Sohn aim to make a significant impact on air quality improvement and NOx reduction in Germany. By harnessing the power of photocatalysis, they pave the way for a healthier and more sustainable future.
  • Focus on Environmental Innovation: Both companies share a common vision of driving environmental innovation and promoting green solutions. By integrating photocatalytic properties into their products, they demonstrate their commitment to combating air pollution and creating cleaner urban environments.
  • Collaboration with Industry Leaders: Photocat and C. Hasse & Sohn are collaborating with prominent institutions and industry leaders to advance the adoption of photocatalytic technology and drive positive change in the German market – and by that growing their respective German businesses.
  • Mutual Commitment to Excellence: This partnership reflects the mutual commitment of both companies to excellence, innovation, and sustainability. By working together, they aim to deliver cutting-edge solutions that benefit both the environment and society as a whole.

Jesper Elsgaard, Chief Business Officer of Photocat, commented, "We are thrilled to partner with C. Hasse & Sohn to advance NOx reduction technology in Germany. This partnership exemplifies our mutual focus on driving the adoption of green and sustainable solutions that have a tangible impact on air quality improvement and NOx reduction. Leveraging our extensive patent base, including innovations developed at our headquarters in Denmark, we are confident that together, we can pave the way for a healthier future".

Karsten Seelig, Geschäftsfuhrer of C. Hasse & Sohn, added, "We are excited to embark on this journey with Photocat to integrate their cutting-edge photocatalytic technology into our product portfolio. This partnership underscores our commitment to delivering innovative and air quality solutions to our customers while contributing to environmental sustainability".

Importantly, this partnership with C. Hasse & Sohn will not influence the expectations for the financial performance of 2024.

For further information, please contact:
Jesper Elsgaard
Chief Business Officer
Photocat A/S
Tel: +45 5121 7651


About Photocat:
Photocat is a leading innovator in sustainable solutions, dedicated to harnessing the power of photocatalysis to create a cleaner and more sustainable world. With a focus on cutting-edge technologies and partnerships, Photocat is at the forefront of environmental innovation. Photocat’s shares are listed on Nasdaq Stockholm, First North with the ticker symbol PCAT. The company’s Certified Advisor is Mangold Fondkommission AB.

About C. Hasse & Sohn:
C. Hasse & Sohn is a prominent German bitumen roofing company known for its commitment to quality and innovation. With a rich history spanning over 150 years, C. Hasse & Sohn specializes in providing high-performance roofing solutions for both residential and commercial applications.

Photocat A/S (publ) l Langebjerg 4 DK-4000 Roskilde l Tel: +45 7022 5055 l


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Subsea7 awarded a contract for the Belinda field in the UK North Sea25.5.2024 14:01:09 CEST | Press release

Luxembourg – 25 May 2024 - Subsea7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a sizeable1 contract by Serica Energy, for the Belinda field development south-east of the Triton FPSO. The Belinda field is operated by Serica Energy and located approximately 190 kilometres east of Aberdeen in the UK Central North Sea, with a water depth of 95 metres. The contract scope includes project management, engineering, procurement, construction and installation (EPCI) of a 5-kilometre 8” production pipeline with a 3” piggy-backed gas lift line and an electro-hydraulic controls (EHC) umbilical. Subsea7’s scope also includes associated subsea structures and tie-ins to the Triton Floating Production Storage & Offloading (FPSO) vessel operated by Dana Petroleum, via an existing production manifold near the Triton riser base and for controls at the Evelyn valve skid. Project management and engineering work will commence immediately in Aberdeen. The offshore activities are scheduled

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio25.5.2024 12:15:00 CEST | Press release

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor,demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1 Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1 IgAN is a heterogeneous, progressive, rare kidney disease with a need for effective, targeted therapies6,7; up to 30% of patients with persistent proteinuria (≥1 g/day) progress to kidney failure within 10 years8 Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression Basel, May 25, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atr

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo25.5.2024 12:00:00 CEST | Press release

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2,3Fabhalta showed a favorable safety profile with no new safety signals1C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years4-7; currently there are no treatments approved for C3G7-9 Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, selectively targets the underlying cause of C3G1; late-stage development program ongoing across several other rare diseases10-13 Basel, May 25, 2024 – Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to support

Metasphere Labs Announces Development of Innovative Carbon Credit Protocol for Grid-Scale Batteries24.5.2024 22:05:00 CEST | Press release

VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is excited to announce an innovative initiative aimed at accelerating the decarbonization of the electricity grid through the development of a pioneering carbon credit protocol for grid-scale batteries. Innovative Carbon Credit Protocol The Company is committed to leveraging advanced technology to address critical environmental challenges. The new carbon credit protocol will enable grid-scale batteries to monetize their environmental attributes by generating carbon credits for the carbon reductions achieved through optimized battery operations. This protocol is designed to incentivize the deployment and operation of grid-scale batteries, ensuring they play a pivotal role in the transition to a clean energy future. Submission to Pure Sky Carbon Credit Registry The Company intends to submit this pr

Nokia Corporation: Repurchase of own shares on 24.05.202424.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 24 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 24.05.2024 Espoo, Finland – On 24 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,1533.55CEUX--BATE--AQEU--TQEX--Total362,1533.55 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

HiddenA line styled icon from Orion Icon Library.Eye